Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 2/20 | 0.36 |
| ▸ | SCD | O00767 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25937262 | 0.82 | SCD (0.34) | SCDKDM1AKDM1BAR | |
| SCHEMBL25937298 | 0.77 | MCHR1 (0.40) | MCHR1SCD | |
| SCHEMBL21955116 | 0.73 | SCD (0.55) | SCDKDM1AKDM1BAR | |
| SCHEMBL30901253 | 0.73 | SCD (0.55) | SCDKDM1AKDM1BAR | |
| SCHEMBL15696647 | 0.73 | MCHR1 (0.44) | MCHR1SCD | |
| SCHEMBL25937270 | 0.72 | MCHR1 (0.36) | MCHR1HTR2CHTR2B | |
| SCHEMBL25937275 | 0.72 | MCHR1 (0.36) | MCHR1HTR2CHTR2B | |
| SCHEMBL25937272 | 0.72 | MCHR1 (0.40) | MCHR1KDM1AHTR2CHTR2B | |
| SCHEMBL25937260 | 0.72 | MCHR1 (0.40) | MCHR1KDM1AHTR2CHTR2B | |
| SCHEMBL8762787 | 0.71 | PPOX (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310423-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11707462-B2 | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | BOUNDLESS BIO, INC. (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310423-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | CHEK1, CHEK2, RAD1 | MCHR1 4279/4885SCD 2737/4885KDM1A 1547/4885 |
| US-11707462-B2 | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | CHEK1, CHEK2, RAD1 | MCHR1 4279/4885SCD 2737/4885KDM1A 1547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.